Liquidia Corp
NASDAQ:LQDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Liquidia Corp
Capital Expenditures
Liquidia Corp
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liquidia Corp
NASDAQ:LQDA
|
Capital Expenditures
-$6.3m
|
CAGR 3-Years
-121%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$4.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$10.8B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
What is Liquidia Corp's Capital Expenditures?
Capital Expenditures
-6.3m
USD
Based on the financial report for Dec 31, 2025, Liquidia Corp's Capital Expenditures amounts to -6.3m USD.
What is Liquidia Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-53%
Over the last year, the Capital Expenditures growth was 25%. The average annual Capital Expenditures growth rates for Liquidia Corp have been -121% over the past three years , -53% over the past five years .
